Association between VEGF expression in tumour-associated macrophages and elevated serum VEGF levels in primary colorectal cancer patients

Cancer Biomarkers

Volumn 3, Issue 6, 2007, Pages 325-333

  Gonzalez, Francisco J ^a   Vicioso, Luis ^a,b   Alvarez, Martina ^b   Sevilla, Isabel ^a   Marques, Eduardo ^a   Gallego, Elena ^a   Alonso, Lorenzo ^a   Matilla, Alfredo ^a,b   Alba, Emilio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b UNIVERSIDAD DE MÁLAGA   (Spain)

Author keywords

Angiogenesis; Circulating angiogenic factors; Colorectal cancer; p53; Tumour associated macrophages; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; PROTEIN P53; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; DENSITY; DISEASE ASSOCIATION; ENZYME IMMUNOASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR VOLUME;

EID: 36549082008     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2007-3606     Document Type: Article

References (42)

1. N. Ferrara and T. Davis-Smyth, The biology of vascular endothelial growth factor, Endocrine Reviews 18 (1997), 4-25.
2. S.B. Fox, G. Gasarini and A.L. Harris, Angiogenesis: Pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs, Lancet Oncology 2 (2001), 278-289.
3. A.M. Jubb, T.H. Landon, J. Burwick, T.Q. Pham, G.D. Frantz, B. Cairns, P. Quirke, F.V. Peale and K.J. Hillan, Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization, Journal Pathology 200 (2003), 577-288.
4. V. Hanrahan, M.J. Currie, S.P. Gunningham, H.R. Morrin, P.A. Scott, B.A. Robinson and S.B. Fox, The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression, Journal Pathology 200 (2003), 183-194.
5. T. Nakasaki, H. Wada, C. Shigemori, C. Miki, E.C. Gabazza, T. Nobori, S. Nakamura and H. Shiku, Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer, American Journal Hematology 69 (2002), 247-254.
6. L. Kaklamanis, M. Trichas, K. Amarantidis, N. Spathari, A. Micheli, A. Karayiannakis, E. Chatzaki, V. Georgoulias and S. Kakolyris, VEGF expression in the colorectal adenomacarcinoma, Oncology Research 15 (2006), 4454-4451.
7. Y. Takahashi, C.D. Bucana, K.R. Cleary and L.M. Ellis, p53, vessel count, and vascular endothelial growth factor expression in human colon cancer, International Journal Cancer 79 (1998), 34-38.
8. H. Kumar, K. Heer, P.W. Lee, G.S. Duthie, A.W. MacDonald, J. Greenman, M.J. Kerin and J.R. Monson, Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer, Clinical Cancer Research 4 (1998), 1279-1285.
9. R.M. Roumen, G.D. Slooter, EA. Croiset van Uchelen and L.V. Huib, Preoperative serum vascular endothelial growth factor is not a marker for subsequent recurrence during longterm follow-up of colorectal cancer patients, Diseases Colon Rectum 48 (2005), 1070-1075.
10. J.S. Lewis, R.J. Landers, J.C. Underwood, A.L. Harris and C.E. Lewis, Expression of vascular endothelial growth factor by macrophages is upregulated in poorly vascularized areas of breast carcinomas, Journal Pathology 192 (2000), 150-158.
11. D. Fukumura, R. Xavier, T. Sugiura, Y. Chen, E.C. Park, N. Lu, M. Selig, G. Nielsen, T. Taksir, R.K. Jain and B. Seed, Tumour induction of VEGF promoter activity in stromal cells, Cell 94 (1998), 715-725.
12. J.L. Yu and J.W. Rak, Host microenvironment in breast cancer development: Inflammatory and immune cells in tumour angiogenesis and arteriogenesis, Breast Cancer Research 5 (2003), 83-88.
13. I. Esposito, M. Menicagli, N. Funel, F. Bergmann, U. Boggi, F. Mosca, G. Bevilacqua and D. Campani, Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma, Journal Clinical Pathology 57 (2004), 630-636.
14. A.A. Khorana, C.K. Ryan, C. Cox, S. Eberly and D.M. Sahasrabudhe, Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma: A role for the host response in prognosis, Cancer 97 (2003), 960-968.
15. E. Barbera-Guillem, J.K. Nyhus, C.C. Wofford, C.R. Friece and J.W. Sampsel, Vascular endothelial growth factor secretion by tumour-infiltrating macrophages essentially supports tumour angiogenesis, and IgG immune complexes potentiate the process, Cancer Research 62 (2002), 7042-7049.
16. L. Vicioso, F.J. Gonzalez, M. Alvarez, N. Ribelles, M. Molina, A. Marquez, L. Perez, A. Matilla and E. Alba, Elevated serum levels of vascular endothelial growth factor are associated with tumour-associated macrophages in primary breast cancer, American Journal Clinical Pathology 125 (2006), 111-118.
17. M.L. George, S.A. Eccles, M.G. Tutton, A.M. Abulafi and I. Swiff, Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: Clinical evidence ofplatelet scavenging? Clinical Cancer Research 6 (2000), 3147-3152.
18. C. Cadwell and G.P. Zambetti, The effects of wild-type p53 tumour suppressor activity and mutant p53 gain-of-function on cell growth, Gene 277 (2001), 15-30.
19. G. Perrone, B. Vincenzi, D. Santini, A. Verzi, G. Tonini, A. Vetrani and C. Rabitti, Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer, Cancer Letter 208 (2004), 227-234.
20. W. Famulski, M. Sulkowska, A. Wincewicz, B. Kedra, K. Pawlak, B. Zalewski, S. Sulkowski, M. Koda and M. Baltaziak, p53 correlates positively with VEGF in preoperative sera of colorectal cancer patients, Neoplasma 53 (2006), 43-48.
21. C.C. Compton, L.P. Fielding, L.J. Burgart, B. Conley, H.S. Cooper, S.R. Hamilton, M.E. Hammond, D.E. Henson, R.V. Hutter, R.B. Nagle, M.L. Nielsen, D.J. Sargent, C.R. Taylor, M. Welton and C. Willett, Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999, Archives Pathology Laboratory Medicine 124 (2000), 979-994.
22. R. Carmona, D. Macias, J.A. Guadix, V. Portillo, J.M. Perez-Pomares, R. Muñoz-Chapuli. A simple technique of image análisis for specific nuclear immunolocalization of proteins, Journal Microscopy 225 (2007), 96-99.
23. P. Salven, A. Orpana and H. Joensuu, Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor, Clinical Cancer Research 5 (1999), 487-491.
24. S.Y. Tan, Y. Fan, H.S. Luo, Z.X. Zhen, Y. Guo and L.J. Zhao, Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer, World Journal Gastroenterology 11 (2005), 1210-1214.
25. Y. Nakayama, N. Nagashima, N. Minigawa, Y. Inoue, T. Katsuki, K. Onitsuka, T. Sako, K. Hirata, N. Nagata and H. Itoh, Relationships between tumour-associated macrophages and clinicopathological factors in patients with colorectal cancer, Anticancer Research 22 (2002), 4291-4296.
26. R.D. Leek, C.E. Lewis, R. Whitehouse, M. Greenall, J. Clarke and A.L. Harris, Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma, Cancer Research 56 (1996), 4625-4629.
27. T. Hanada, M. Nakagawa, A. Emoto, T. Nomura, N. Nasu and Y. Nomura, Prognostic value of tumour-associated macrophage count in human bladder cancer, International Journal Urology 7 (2000), 263-269.
28. H. Kuniyasu, T. Sasaki, T. Sasahira, H. Ohmori and T. Takahashi, Depletion of tumour-infiltrating macrophages is associated with amphoterin expression in colon cancer, Pathobiology 71 (2004), 129-136.
29. D. Murray, A. Hreno, J. Dutton and L.G Hampson, Prognosis in colon cancer: A pathologic reassessment, Archives Surgery 110 (1975), 908-913.
30. I.D. Nagtegaal, C.A. Marijnen, E.K. Kranenbarg, A. Mulder-Stapel, J. Hermans, C.J. van de Velde and J.H. van Krieken, Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-a histopathological and immunohistochemical study, BMC Cancer 1 (2001), 7.
31. T. Etoh, K. Shibuta, G.F. Barnard, S. Kitano and M. Mori, Angiogenin expression in human colorectal cancer: The role of focal macrophage infiltration, Clinical Cancer Research 6 (2000), 3545-3551.
32. R.D. Leek, N.C. Hunt, R.J. Landers, C.E. Lewis, J.A. Royds and A.L. Harris, Macrophage infiltration is associated with VEGF and EGER expression in breast cancer, Journal Pathology 190 (2000), 430-436.
33. T. Valkovic, F. Dobrila, M. Melato, F. Sasso, C. Rizzardi and N. Jonjic, Correlation between vascular endothelial growth factor, angiogenesis, and tumour-associated macrophages in invasive ductal breast carcinoma, Virchows Archives 440 (2002), 583-588.
34. J. Mullerat, C.W. Perrett, F. Deroide, M.C. Winslet, M. Bofill and L.W. Poulter, The role of macrophages in angiogenesis. Comparison between HIV+ and HIV- populations with anal dysplasia and anal cancer, Anticancer Research 25 (2006), 693-700.
35. S.J. Oosterling, G.J. van der Bij, G.A. Meijer, C.W. Tuk, E. van Garderen, N. van Rooijen, S. Meijer, J.R. van der Sijp, R.H. Beelen RH and M. van Egmond, Macrophages direct tumour histology and clinical outcome in a colon cancer model, Journal Pathology 207 (2005), 147-155.
36. B. Burke, A. Giannoudis, K.P. Corke, D. Gill, M. Wells, L. Ziegler-Heitbrock and C.E. Lewis, Hypoxia-induced gene expression in human macrophages: Implications for ischemic tissues and hypoxia-regulated gene therapy, American Journal Pathology 163 (2003), 1233-1243.
37. P. Faviana, L. Boldrini, R. Spisni, P. Berti, D. Galleri, R. Biondi, T. Cammaci, G. Materazzi, R. Pingitore, P. Miccoli and G. Fontanini, Neoangiogenesis in colon cancer: Correlation between vascular density, vascular endothelial growth factor (VEGF) and p53 protein expression Oncology Reports 9 (2002), 617-620.
38. Y. Kondo, S. Arii, N. Furutami, S. Isigami, A. Mori, H. Onodera, T. Chiba and M. Imamma, Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma, Cancer 88 (2000), 1820-1827.
39. R. Broll, H. Erdmann, M. Duchrow, E. Oevermann, O. Schwandner, U. Marker, H.P. Bruch and U. Windhovel, Vascular endothelial growth factor (VEGF)- a valuable serum tumour marker in patients with colorectal cancer?, European Journal Surgery Oncology 27 (2001), 37-42.
40. R. Cressey, O. Wattananupong, N. Lertprasertsuke and U. Vinitketkumnuen, Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis, BMC Cancer 5 (2005), 128.
41. A.J. Karayiannakis, K.N. Syrigos, A. Zbar, N. Baibas, A. Polychronidis, C. Simopoulos and G. Karatzas, Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumour surgery, Surgery 131 (2002), 548-555.
42. T. Cubo, D. Padilla, G. de la Osa, T. Palomino, M. Garcia, R. Pardo, J. Martin, E. Arevalo and J. Hernandez, Serum vascular endothelial growth factor levels in patients with colorectal cancer and its prognostic significance, Medicina Clinica (Barcelona) 122 (2004), 201-204.